AVCRF logo

Avricore Health Inc. (AVCRF)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Mit einem Kurs von $ ist Avricore Health Inc. (AVCRF) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 57/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.

Zuletzt analysiert: 17. März 2026
57/100 KI-Bewertung

Avricore Health Inc. (AVCRF) Gesundheitswesen & Pipeline-Uebersicht

CEORodger Seccombe
HauptsitzVancouver, CA
IPO-Jahr2009

Avricore Health Inc. provides the HealthTab point-of-care testing platform, enabling lab-accurate diagnostics in pharmacies. The company focuses on health data and technology solutions within the Canadian healthcare market, leveraging partnerships with major players like Shoppers Drug Marts and Abbott to expand its reach and service offerings.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 17. März 2026

Investmentthese

Avricore Health Inc. presents a focused investment opportunity within the point-of-care diagnostics market in Canada. The company's HealthTab platform, offering lab-accurate testing in pharmacies, addresses the increasing demand for accessible and convenient healthcare solutions. Strategic partnerships with Shoppers Drug Marts and Abbott provide a strong foundation for market penetration and expansion. However, the company's negative P/E ratio of -4.35 and a profit margin of -84.7% indicate significant challenges in achieving profitability. The low beta of 0.31 suggests relatively low volatility compared to the market. Key value drivers include expanding the HealthTab platform's test menu, securing additional pharmacy partnerships, and leveraging health data for personalized healthcare solutions. The path to profitability and sustainable growth remains a critical factor for investors to consider.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market Cap of $0.01B indicates a small-cap company with potential for growth but also higher risk.
  • P/E Ratio of -4.35 reflects the company's current lack of profitability.
  • Gross Margin of 43.4% suggests a viable business model with potential for profitability if costs are managed effectively.
  • Beta of 0.31 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.
  • Strategic partnerships with Shoppers Drug Marts and Abbott provide a strong foundation for market access and credibility.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Proprietary HealthTab platform.
  • Strategic partnerships with Shoppers Drug Marts and Abbott.
  • Focus on point-of-care testing.
  • Experienced management team.

Schwaechen

  • Negative P/E ratio and low profitability.
  • Limited market presence outside of Canada.
  • Dependence on key partnerships.
  • Limited financial resources.

Katalysatoren

  • Ongoing: Expansion of the HealthTab platform's test menu to include additional diagnostic tests.
  • Ongoing: Securing new partnerships with pharmacy chains and independent pharmacies across Canada.
  • Upcoming: Potential integration of the HealthTab platform with telehealth platforms by 2027.
  • Upcoming: Possible geographic expansion beyond Canada by 2029.
  • Ongoing: Leveraging health data for personalized healthcare solutions and services.

Risiken

  • Potential: Competition from established diagnostic companies with greater resources and market share.
  • Potential: Regulatory changes in the healthcare industry that could impact the adoption of point-of-care testing.
  • Potential: Technological advancements that could render the HealthTab platform obsolete.
  • Ongoing: Limited financial resources and profitability challenges.
  • Ongoing: Dependence on key partnerships with Shoppers Drug Marts and Abbott.

Wachstumschancen

  • Expanding the HealthTab platform's test menu: Avricore Health can drive growth by continually expanding the range of diagnostic tests available on the HealthTab platform. This includes incorporating tests for chronic diseases, infectious diseases, and other common health conditions. The point-of-care diagnostics market is projected to reach $40 billion by 2028, offering a significant opportunity for Avricore Health to capture market share by offering a comprehensive testing solution. Timeline: Ongoing.
  • Securing additional pharmacy partnerships: Building on existing partnerships with Shoppers Drug Marts, Avricore Health can pursue collaborations with other pharmacy chains and independent pharmacies across Canada. Expanding the network of HealthTab-enabled pharmacies will increase accessibility and drive revenue growth. The Canadian pharmacy market is estimated at $35 billion annually, providing a large potential customer base for Avricore Health's services. Timeline: Ongoing.
  • Leveraging health data for personalized healthcare solutions: Avricore Health can leverage the data collected through the HealthTab platform to develop personalized healthcare solutions and services. This includes offering tailored health recommendations, disease management programs, and remote patient monitoring services. The personalized medicine market is expected to reach $2.4 billion by 2027, presenting a significant growth opportunity for Avricore Health. Timeline: 2027.
  • Geographic expansion beyond Canada: While currently focused on the Canadian market, Avricore Health can explore opportunities to expand its operations to other countries with similar healthcare systems and market dynamics. This could include entering the US market or partnering with international pharmacy chains to deploy the HealthTab platform globally. The global point-of-care diagnostics market is projected to reach $50 billion by 2029, offering a vast potential market for Avricore Health's expansion. Timeline: 2029.
  • Integrating with telehealth platforms: Avricore Health can integrate the HealthTab platform with telehealth platforms to provide remote diagnostic testing and virtual healthcare services. This would enable patients to access diagnostic testing from the comfort of their homes and receive virtual consultations with healthcare providers. The telehealth market is expected to reach $55 billion by 2027, creating a synergistic opportunity for Avricore Health to expand its service offerings. Timeline: 2027.

Chancen

  • Expanding the HealthTab platform's test menu.
  • Securing additional pharmacy partnerships.
  • Leveraging health data for personalized healthcare solutions.
  • Geographic expansion beyond Canada.

Risiken

  • Competition from established diagnostic companies.
  • Regulatory changes in the healthcare industry.
  • Technological advancements that could render the HealthTab platform obsolete.
  • Economic downturn that could reduce healthcare spending.

Wettbewerbsvorteile

  • Strategic partnerships with Shoppers Drug Marts and Abbott provide a competitive advantage.
  • Proprietary HealthTab platform offers a unique point-of-care testing solution.
  • Focus on health data and personalized healthcare solutions creates differentiation.

Ueber AVCRF

Avricore Health Inc., originally founded as Vanc Pharmaceuticals Inc. in 1996 and rebranded in October 2018, is a Canadian company focused on point-of-care technologies and health data solutions. Headquartered in Vancouver, the company's primary offering is HealthTab, a platform designed to provide lab-accurate diagnostic testing within pharmacy settings. This technology allows for convenient and accessible health monitoring, catering to the growing demand for decentralized healthcare services. Through HealthTab, Avricore Health aims to bridge the gap between traditional lab testing and immediate patient needs, offering a range of diagnostic tests directly in pharmacies. The company has established strategic partnerships with Shoppers Drug Marts and Abbott, enhancing its market reach and credibility within the Canadian healthcare landscape. These collaborations enable Avricore Health to integrate its technology into established pharmacy networks, providing a seamless experience for both healthcare providers and patients. Avricore Health continues to innovate and expand its HealthTab platform, focusing on delivering accessible and reliable health data solutions to improve patient outcomes and streamline healthcare delivery.

Was das Unternehmen tut

  • Provides the HealthTab platform for lab-accurate point-of-care testing.
  • Enables diagnostic testing within pharmacy settings.
  • Offers a range of diagnostic tests directly in pharmacies.
  • Bridges the gap between traditional lab testing and immediate patient needs.
  • Integrates technology into established pharmacy networks.
  • Delivers accessible and reliable health data solutions.

Geschaeftsmodell

  • Generates revenue through the sale and licensing of the HealthTab platform.
  • Partners with pharmacies to offer diagnostic testing services.
  • Collects and analyzes health data to provide personalized healthcare solutions.

Branchenkontext

Avricore Health Inc. operates within the rapidly evolving medical diagnostics and research industry, driven by increasing demand for point-of-care testing and personalized healthcare solutions. The market is characterized by technological advancements, regulatory changes, and shifting consumer preferences towards accessible and convenient healthcare services. Competitors include companies like AVTBF (Avant Technologies Inc.), BBRRF (Biome Grow Inc.), BUDZ (BUDZ, INC.), ICBU (ICB International Consolidated Business Corp), and IDXG (IDEXX Laboratories, Inc.), each offering various diagnostic solutions and technologies. Avricore Health's focus on pharmacy-based testing positions it within a niche segment of the market, leveraging the accessibility and convenience of pharmacies to deliver diagnostic services.

Wichtige Kunden

  • Pharmacies seeking to offer point-of-care diagnostic testing.
  • Patients seeking convenient and accessible health monitoring.
  • Healthcare providers seeking to improve patient outcomes.
KI-Zuversicht: 71% Aktualisiert: 17. März 2026

Finanzdaten

Chart & Info

Avricore Health Inc. (AVCRF) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Keine aktuellen Nachrichten fuer AVCRF verfuegbar.

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer AVCRF.

Kursziele

Wall-Street-Kurszielanalyse fuer AVCRF.

MoonshotScore

57/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von AVCRF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Klassifizierung

Sektor Healthcare Branche Medical - Diagnostics & Research

Fuehrung: Rodger Seccombe

CEO

Rodger Seccombe is the CEO of Avricore Health Inc. His background includes extensive experience in the healthcare and technology sectors. He has held various leadership positions in companies focused on developing and commercializing innovative healthcare solutions. Seccombe's expertise lies in strategic planning, business development, and market execution. He is responsible for driving Avricore Health's growth strategy and expanding the adoption of the HealthTab platform.

Erfolgsbilanz: Under Rodger Seccombe's leadership, Avricore Health has focused on expanding its HealthTab platform and securing strategic partnerships. Key milestones include the partnerships with Shoppers Drug Marts and Abbott, which have significantly enhanced the company's market reach and credibility. Seccombe has also overseen the development of new features and functionalities for the HealthTab platform, enhancing its value proposition for pharmacies and patients.

AVCRF OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the OTC market, indicating that Avricore Health Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited regulatory oversight and may not be required to provide audited financial statements. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity. These companies often face challenges in attracting institutional investors and may be subject to greater price volatility compared to companies listed on major exchanges.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Liquidity for AVCRF is likely limited due to its OTC listing. Expect wider bid-ask spreads compared to NYSE or NASDAQ-listed stocks. Trading may be difficult, particularly for large orders, and price slippage is a potential concern. Volume may be thin, making it harder to enter or exit positions quickly. Investors should exercise caution and use limit orders to manage risk.
OTC-Risikofaktoren:
  • Limited regulatory oversight compared to major exchanges.
  • Potential for limited financial disclosure.
  • Higher price volatility due to thin trading volume.
  • Increased risk of fraud or manipulation.
  • Difficulty in obtaining accurate and timely information.
Sorgfaltspruefung-Checkliste:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's legal and regulatory compliance.
  • Check for any red flags or warning signs.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before investing.
Legitimitaetssignale:
  • Strategic partnerships with reputable companies like Shoppers Drug Marts and Abbott.
  • Proprietary HealthTab platform with a clear value proposition.
  • Experienced management team with a track record in the healthcare industry.
  • Focus on addressing a growing need for point-of-care testing.
  • Positive customer feedback and testimonials.

AVCRF Healthcare Aktien-FAQ

What are the key factors to evaluate for AVCRF?

Avricore Health Inc. (AVCRF) currently holds an AI score of 57/100, indicating moderate score. Key strength: Proprietary HealthTab platform.. Primary risk to monitor: Potential: Competition from established diagnostic companies with greater resources and market share.. This is not financial advice.

How frequently does AVCRF data refresh on this page?

AVCRF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven AVCRF's recent stock price performance?

Recent price movement in Avricore Health Inc. (AVCRF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary HealthTab platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider AVCRF overvalued or undervalued right now?

Determining whether Avricore Health Inc. (AVCRF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying AVCRF?

Before investing in Avricore Health Inc. (AVCRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding AVCRF to a portfolio?

Potential reasons to consider Avricore Health Inc. (AVCRF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary HealthTab platform.. Additionally: Strategic partnerships with Shoppers Drug Marts and Abbott.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of AVCRF?

Yes, most major brokerages offer fractional shares of Avricore Health Inc. (AVCRF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track AVCRF's earnings and financial reports?

Avricore Health Inc. (AVCRF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for AVCRF earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Financial data is based on the most recently available information.
  • OTC market data may be limited or less reliable than data for major exchanges.
  • AI analysis is pending and may provide additional insights in the future.
Datenquellen

Popular Stocks